Procalcitonin (PCT) Predicts Worse Outcome in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF)

Table 2

Comparison of white blood cell count (WBC), procalcitonin (PCT), and high sensitivity C-reactive protein (hsCRP) plasma concentration in patients with chronic heart failure: stable and exacerbated and in controls.

Group	Minimum	Lower quartile	Median	Upper quartile	Maximum
Procalcitonin [pg/ml]
Control	1.19	13.00	22.15	48.74	200	<0.0001
CHF all	14.71	112.27	166.95	284.53	927
CHF stable	14.71	118.65	163.71	280.47	800.24
CHF exacerbation	22.83	105.46	175.19	286.54	927.00
hsCRP [mg/l]
Control	0.3	1.7	2.2	2.5	6.6	<0.01
CHF all	0.6	1.9	4.0	7.8	48
CHF stable	0.6	1.6	3.4	7.2	23.7
CHF exacerbation	0.8	2.1	4.6	8.2	48
WBC [G/l]
Control	4.61	5.70	6.27	8.87	9.18	ns
CHF all	4.03	5.98	7.32	11.12	13.74
CHF stable	4.83	6.10	7.28	11.23	13.74
CHF exacerbation	4.03	5.65	7.37	10.91	12.82

^∗Difference between CHF all and controls.